Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?

This article was originally published in The Pink Sheet Daily

Executive Summary

The diet pill was not approved or recommended for use in about 90 percent of patients in the trial that triggers the warning, Abbott says.

You may also be interested in...



Eisai's High Dose Aricept Beats Expectations, But Lack Of Solutions Plague Mid-term Forecast

TOKYO - A higher-dose Aricept anti-Alzheimer treatment U.S. FDA approved this summer is set to be a core revenue contributor for Eisai through its business year ending next March and on, and if its endotoxin antagonist eritoran for severe sepsis is approved, the growth momentum could continue through 2012, according to Eisai and analysts

Vivus' Qnexa Gets "Complete Response" Letter From FDA

FDA wants more data on risk of birth defects, cardiovascular effects, but doesn't ask for new clinical trials - at least for now.

Vivus' Qnexa Gets "Complete Response" Letter From FDA

FDA wants more data on risk of birth defects, cardiovascular effects, but doesn't ask for new clinical trials - at least for now.

Related Content

Topics

UsernamePublicRestriction

Register

PS068797

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel